AI-based decision support system for cancer care
Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care
This study is testing an AI tool that helps doctors make better treatment decisions for patients with stomach and esophagus cancers to improve care, especially in places with fewer resources.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | National University Hospital, Singapore Academic / other |
| Locations | 9 sites (Leipzig and 8 other locations) |
| Trial ID | NCT04675138 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a Clinical Decision Support System (CDSS) that utilizes artificial intelligence to enhance decision-making in the treatment of gastric and esophageal cancers. The system will leverage international guidelines and high-quality evidence to provide case-specific treatment recommendations. It will be evaluated by comparing its recommendations with those from multidisciplinary tumor boards at various tertiary care institutions to assess concordance rates. The goal is to improve cancer care delivery, especially in centers with limited resources.
Who should consider this trial
Good fit: Ideal candidates include patients with primary gastric adenocarcinoma, gastroesophageal junction cancers, or esophageal cancer.
Not a fit: Patients with other types of cancers or those participating in non-standard treatment clinical trials may not benefit from this study.
Why it matters
Potential benefit: If successful, this system could significantly improve treatment decision-making for patients with gastric and esophageal cancers.
How similar studies have performed: Previous studies have shown that Clinical Decision Support Systems can enhance patient safety and diagnostic accuracy, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
A. In discovery and internal retrospective validation part: 1. Patients with primary gastric adenocarcinoma including preinvasive carcinoma or 2. Patients with gastroesophageal junction cancers or 3. Patients with oesophageal cancer including adenocarcinoma, squamous cell carcinoma and preinvasive carcinoma subtypes. B. In prospective validation part: 1. Patients with primary gastric adenocarcinoma including preinvasive carcinoma or 2. Patients with esophageal or gastroesophageal junction adenocarcinoma Exclusion Criteria: A. In discovery and internal retrospective validation part: 1. Patients with other primary cancers involving the stomach or oesophagus 2. Patients with other cancer subtypes 3. Patients with concomitant cancers of other organs B. In prospective validation part: 1. Patients with esophageal squamous cell carcinoma 2. Patients who participate in clinical trials where the treatment modality is not standard of care
Where this trial is running
Leipzig and 8 other locations
- University Hospital Leipzig — Leipzig, Germany (Recruiting)
- National Cancer Centre Hospital East — Kashiwa, Japan (Recruiting)
- National University Hospital — Singapore, Singapore (Recruiting)
- National Cancer Centre Singapore — Singapore, Singapore (Recruiting)
- Ng Teng Feng General Hospital — Singapore, Singapore (Recruiting)
- Tan Tock Seng Hospital — Singapore, Singapore (Recruiting)
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
- Karolinska Institute Hospital — Stockholm, Sweden (Recruiting)
- The University of Edinburgh — Edinburgh, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Bok Yan, Jimmy So
- Email: sursbyj@nus.edu.sg
- Phone: +65 6772 5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.